Clinical Trial

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-14; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2026-01-30
Trial Details
NCT Number NCT07230730
Lead Sponsor Beijing Suncadia Pharmaceuticals Co., Ltd
Conditions Hyperlipidemia
Enrollment 900 participants
Start Date 2026-01-13
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-14